S&P 500   3,111.47 (-0.04%)
DOW   27,630.64 (-0.07%)
QQQ   202.33 (-0.05%)
AAPL   264.52 (+1.06%)
MSFT   149.78 (-0.05%)
GOOGL   1,317.78 (-0.09%)
AMZN   1,743.56 (-0.97%)
MU   46.42 (+0.26%)
BABA   199.77 (+3.11%)
GE   10.82 (-0.83%)
TSLA   330.70 (-0.70%)
T   38.31 (+0.55%)
PRI   134.32 (+0.84%)
NFLX   299.63 (-1.54%)
BAC   33.10 (-0.15%)
S&P 500   3,111.47 (-0.04%)
DOW   27,630.64 (-0.07%)
QQQ   202.33 (-0.05%)
AAPL   264.52 (+1.06%)
MSFT   149.78 (-0.05%)
GOOGL   1,317.78 (-0.09%)
AMZN   1,743.56 (-0.97%)
MU   46.42 (+0.26%)
BABA   199.77 (+3.11%)
GE   10.82 (-0.83%)
TSLA   330.70 (-0.70%)
T   38.31 (+0.55%)
PRI   134.32 (+0.84%)
NFLX   299.63 (-1.54%)
BAC   33.10 (-0.15%)
S&P 500   3,111.47 (-0.04%)
DOW   27,630.64 (-0.07%)
QQQ   202.33 (-0.05%)
AAPL   264.52 (+1.06%)
MSFT   149.78 (-0.05%)
GOOGL   1,317.78 (-0.09%)
AMZN   1,743.56 (-0.97%)
MU   46.42 (+0.26%)
BABA   199.77 (+3.11%)
GE   10.82 (-0.83%)
TSLA   330.70 (-0.70%)
T   38.31 (+0.55%)
PRI   134.32 (+0.84%)
NFLX   299.63 (-1.54%)
BAC   33.10 (-0.15%)
S&P 500   3,111.47 (-0.04%)
DOW   27,630.64 (-0.07%)
QQQ   202.33 (-0.05%)
AAPL   264.52 (+1.06%)
MSFT   149.78 (-0.05%)
GOOGL   1,317.78 (-0.09%)
AMZN   1,743.56 (-0.97%)
MU   46.42 (+0.26%)
BABA   199.77 (+3.11%)
GE   10.82 (-0.83%)
TSLA   330.70 (-0.70%)
T   38.31 (+0.55%)
PRI   134.32 (+0.84%)
NFLX   299.63 (-1.54%)
BAC   33.10 (-0.15%)
Log in

NYSE:PFE - Pfizer Stock Price, Forecast & News

$38.07
-0.07 (-0.18 %)
(As of 12/5/2019 01:31 PM ET)
Today's Range
$37.79
Now: $38.07
$38.43
50-Day Range
$36.31
MA: $37.51
$38.65
52-Week Range
$33.97
Now: $38.07
$44.99
Volume348,356 shs
Average Volume23.17 million shs
Market Capitalization$210.68 billion
P/E Ratio12.69
Dividend Yield3.78%
Beta0.66
Pfizer Inc discovers, develops, manufactures, and sells healthcare products worldwide. It offers medicines and vaccines in various therapeutic areas, including internal medicine, vaccines, oncology, inflammation and immunology, and rare diseases under the Lyrica, Chantix/Champix, Eliquis, Ibrance, Sutent, Xalkori, Inlyta, Xtandi, Enbrel, Xeljanz, Eucrisa, BeneFix, Genotropin, and Refacto AF/Xyntha brands. Read More…

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryPharmaceuticals
SectorMedical
CUSIP71708110
Phone212-733-2323

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$53.65 billion
Cash Flow$4.16 per share
Book Value$11.03 per share

Profitability

Net Income$11.15 billion

Miscellaneous

Employees92,400
Outstanding Shares5,534,123,000
Market Cap$210.68 billion
Next Earnings Date2/4/2020 (Estimated)
OptionableOptionable

Receive PFE News and Ratings via Email

Sign-up to receive the latest news and ratings for PFE and its competitors with MarketBeat's FREE daily newsletter.


Pfizer (NYSE:PFE) Frequently Asked Questions

What is Pfizer's stock symbol?

Pfizer trades on the New York Stock Exchange (NYSE) under the ticker symbol "PFE."

How often does Pfizer pay dividends? What is the dividend yield for Pfizer?

Pfizer declared a quarterly dividend on Tuesday, September 24th. Shareholders of record on Friday, November 8th will be paid a dividend of $0.36 per share on Monday, December 2nd. This represents a $1.44 dividend on an annualized basis and a yield of 3.78%. The ex-dividend date of this dividend is Thursday, November 7th. View Pfizer's Dividend History.

How will Pfizer's stock buyback program work?

Pfizer declared that its Board of Directors has approved a stock repurchase program on Friday, December 14th 2018, which permits the company to repurchase $10,000,000,000.00 in outstanding shares, according to EventVestor. This repurchase authorization permits the company to repurchase up to 3.8% of its stock through open market purchases. Stock repurchase programs are usually an indication that the company's leadership believes its stock is undervalued.

How were Pfizer's earnings last quarter?

Pfizer Inc. (NYSE:PFE) issued its earnings results on Tuesday, October, 29th. The biopharmaceutical company reported $0.75 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.62 by $0.13. The biopharmaceutical company had revenue of $12.68 billion for the quarter, compared to analysts' expectations of $12.37 billion. Pfizer had a return on equity of 28.10% and a net margin of 30.57%. The company's revenue for the quarter was down 4.6% compared to the same quarter last year. During the same period in the prior year, the business earned $0.78 earnings per share. View Pfizer's Earnings History.

When is Pfizer's next earnings date?

Pfizer is scheduled to release their next quarterly earnings announcement on Tuesday, February 4th 2020. View Earnings Estimates for Pfizer.

What guidance has Pfizer issued on next quarter's earnings?

Pfizer issued an update on its FY19 earnings guidance on Tuesday, October, 29th. The company provided earnings per share (EPS) guidance of $2.94-3.00 for the period, compared to the Thomson Reuters consensus EPS estimate of $2.82. The company issued revenue guidance of $51.2-52.2 billion, compared to the consensus revenue estimate of $51.47 billion.

What price target have analysts set for PFE?

11 brokers have issued 1 year price targets for Pfizer's stock. Their forecasts range from $36.00 to $55.00. On average, they anticipate Pfizer's stock price to reach $43.66 in the next twelve months. This suggests a possible upside of 14.7% from the stock's current price. View Analyst Price Targets for Pfizer.

What is the consensus analysts' recommendation for Pfizer?

11 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Pfizer in the last year. There are currently 8 hold ratings and 3 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Pfizer.

What are Wall Street analysts saying about Pfizer stock?

Here are some recent quotes from research analysts about Pfizer stock:
  • 1. According to Zacks Investment Research, "The Consumer Healthcare joint venture with Glaxo, the Array acquisition and the pending merger of Upjohn unit with Mylan, if successful, will make Pfizer a smaller company with a diversified portfolio of innovative drugs and vaccines. The smaller Pfizer should see better revenue growth as the Lyrica LOE cliff will go away. Pfizer expects continued strong growth of key brands like Ibrance and Eliquis and biosimilars to drive sales in the second half. Pfizer is also strengthening its pipeline and hopes to launch new innovative medicines in the next five years, which can drive long-term growth. However, currency headwinds, weak sales in the sterile injectables portfolio, pricing pressure and some recent negative product developments for Prevnar and Xeljanz, are top-line headwinds. Shares have underperformed the industry this year so far. " (10/1/2019)
  • 2. Cantor Fitzgerald analysts commented, "We reiterate our OW rating and think respectable earnings growth, driven by Innovative Medicines, pipeline advancements, and return of capital to PFE’s shareholders — above the industry average — are all underappreciated. Therefore, we believe multiple expansion and upward earnings revisions should drive PFE shares higher. Valuation Summary We use a blend of DCF and multiples (EV/EBITDA) analysis to get to our 12-month price target of $53." (2/19/2019)

Has Pfizer been receiving favorable news coverage?

Media coverage about PFE stock has been trending somewhat positive recently, InfoTrie Sentiment reports. The research group identifies negative and positive news coverage by reviewing more than six thousand news and blog sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores closest to five being the most favorable. Pfizer earned a coverage optimism score of 0.9 on InfoTrie's scale. They also gave headlines about the biopharmaceutical company a news buzz of 1.0 out of 10, meaning that recent news coverage is extremely unlikely to have an impact on the stock's share price in the near future. View News Stories for Pfizer.

Who are some of Pfizer's key competitors?

What other stocks do shareholders of Pfizer own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Pfizer investors own include AT&T (T), Cisco Systems (CSCO), Johnson & Johnson (JNJ), Verizon Communications (VZ), General Electric (GE), Intel (INTC), Bank of America (BAC), Exxon Mobil (XOM), AbbVie (ABBV) and Merck & Co., Inc. (MRK).

Who are Pfizer's key executives?

Pfizer's management team includes the folowing people:
  • Mr. Ian C. Read, Exec. Chairman (Age 65)
  • Mr. Albert Bourla D.V.M., DVM, Ph.D., CEO & Director (Age 57)
  • Mr. Frank A. D'Amelio, CFO & EVP of Global Supply & Bus. Operations (Age 61)
  • Dr. Mikael Dolsten, Chief Scientific Officer & Pres of Worldwide Research, Devel. and Medical (Age 60)
  • Mr. John D. Young, Group Pres & Chief Bus. Officer (Age 54)

Who are Pfizer's major shareholders?

Pfizer's stock is owned by a number of of institutional and retail investors. Top institutional shareholders include State Street Corp (5.25%), Massachusetts Financial Services Co. MA (1.00%), Fisher Asset Management LLC (0.82%), Sumitomo Mitsui Trust Holdings Inc. (0.41%), California Public Employees Retirement System (0.38%) and Parametric Portfolio Associates LLC (0.37%). Company insiders that own Pfizer stock include Alexander R Mackenzie, Charles H Hill, Dawn Rogers, Douglas M Lankler, Frank A Damelio, Ian C Read, Kirsten Lund-Jurgensen, Laurie J Olson, Loretta V Cangialosi, Mikael Dolsten, Pfizer Inc, Rady A Johnson, Sally Susman, Scott Gottlieb and W Don Cornwell. View Institutional Ownership Trends for Pfizer.

Which major investors are selling Pfizer stock?

PFE stock was sold by a variety of institutional investors in the last quarter, including Assenagon Asset Management S.A., State Street Corp, Voya Investment Management LLC, California Public Employees Retirement System, Artemis Investment Management LLP, Parametric Portfolio Associates LLC, Teacher Retirement System of Texas and Miller Howard Investments Inc. NY. Company insiders that have sold Pfizer company stock in the last year include Alexander R Mackenzie, Dawn Rogers, Douglas M Lankler, Frank A Damelio, Mikael Dolsten and Rady A Johnson. View Insider Buying and Selling for Pfizer.

Which major investors are buying Pfizer stock?

PFE stock was acquired by a variety of institutional investors in the last quarter, including DNB Asset Management AS, Eagle Asset Management Inc., Fisher Asset Management LLC, State of Tennessee Treasury Department, Diamond Hill Capital Management Inc., First Trust Advisors LP, Stifel Financial Corp and Sumitomo Mitsui Trust Holdings Inc.. Company insiders that have bought Pfizer stock in the last two years include Pfizer Inc and Scott Gottlieb. View Insider Buying and Selling for Pfizer.

How do I buy shares of Pfizer?

Shares of PFE can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Pfizer's stock price today?

One share of PFE stock can currently be purchased for approximately $38.08.

How big of a company is Pfizer?

Pfizer has a market capitalization of $210.74 billion and generates $53.65 billion in revenue each year. The biopharmaceutical company earns $11.15 billion in net income (profit) each year or $3.00 on an earnings per share basis. Pfizer employs 92,400 workers across the globe.View Additional Information About Pfizer.

What is Pfizer's official website?

The official website for Pfizer is http://www.pfizer.com/.

How can I contact Pfizer?

Pfizer's mailing address is 235 EAST 42ND STREET, NEW YORK NY, 10017. The biopharmaceutical company can be reached via phone at 212-733-2323.


MarketBeat Community Rating for Pfizer (NYSE PFE)

Community Ranking:  3.0 out of 5 (star star star)
Outperform Votes:  1,321 (Vote Outperform)
Underperform Votes:  908 (Vote Underperform)
Total Votes:  2,229
MarketBeat's community ratings are surveys of what our community members think about Pfizer and other stocks. Vote "Outperform" if you believe PFE will outperform the S&P 500 over the long term. Vote "Underperform" if you believe PFE will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 12/5/2019 by MarketBeat.com Staff

Featured Article: What is Call Option Volume?

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel